Swiss National Bank Has $338.08 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Swiss National Bank boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 321,600 shares of the biopharmaceutical company’s stock after buying an additional 2,000 shares during the quarter. Swiss National Bank owned approximately 0.29% of Regeneron Pharmaceuticals worth $338,079,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Quent Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 19 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 37.2% in the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after purchasing an additional 16,856 shares during the period. Jacobi Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Jacobi Capital Management LLC now owns 1,139 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 20 shares during the period. Covestor Ltd lifted its stake in shares of Regeneron Pharmaceuticals by 7.4% in the 1st quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 14 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 17.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock valued at $6,660,000 after purchasing an additional 1,030 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $756.81 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15. The stock has a 50 day moving average of $985.21 and a 200 day moving average of $1,033.97. Regeneron Pharmaceuticals, Inc. has a 12 month low of $753.69 and a 12 month high of $1,211.20.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday. They issued an “outperform” rating and a $1,150.00 target price for the company. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.